Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis: lessons from treatment in adults and the way forward

References

• Murdaca G, Colombo BM, Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern Emerg Med. 2011 Dec;6(6):487–495. doi: 10.1007/s11739-011-0517-7
   PubMed Web of Science ®Google Scholar
• Arican O, Aral M, Sasmaz S, et al. Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005 Oct 24;2005(5):273–279. doi: 10.1155/MI.2005.273
   PubMedGoogle Scholar
• Schett G, Lories RJ, D’Agostino MA, et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol. 2017 Dec;13(12):731–741.
   PubMed Web of Science ®Google Scholar
• McGonagle DG, McInnes IB, Kirkham BW, et al. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019 Sep;78(9):1167–1178.
   PubMed Web of Science ®Google Scholar
• Li X, Yuan FL, Lu WG, et al. The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem Biophys Res Commun. 2010 Jun 25;397(2):131–135. doi: 10.1016/j.bbrc.2010.05.111
   PubMed Web of Science ®Google Scholar
• Lazić E, Jelušić M, Grčević D, et al. Osteoblastogenesis from synovial fluid-derived cells is related to the type and severity of juvenile idiopathic arthritis. Arthritis Res Ther. 2012;14(3):R139. doi: 10.1186/ar3872
   PubMed Web of Science ®Google Scholar
• Nistala K, Wedderburn LR. Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology. 2009 Jun 1;48(6):602–606. doi: 10.1093/rheumatology/kep028
   PubMed Web of Science ®Google Scholar
• Vijatov-Djuric G. Interleukin-17A levels increase in serum of children with juvenile idiopathic arthritis. Arch Rheumatol. 2017 Apr 4;32(3):234–243. doi: 10.5606/ArchRheumatol.2017.6067
   PubMed Web of Science ®Google Scholar
• Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018 Jan;9(1):5–21. doi: 10.1177/2040622317738910
   PubMed Web of Science ®Google Scholar
• Bruin G, Hockey HP, La Stella P, et al. Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients. Br J Clin Pharmacol. 2020 Feb;86(2):338–351.
   PubMed Web of Science ®Google Scholar
• Study Record | Beta ClinicalTrials.gov [Internet]. [cited 2023 May 5]. Available from: https://beta.clinicaltrials.gov/study/NCT03131570?tab=results
   Google Scholar
• Study Record | Beta ClinicalTrials.gov [Internet]. [cited 2023 May 5]. Available from: https://beta.clinicaltrials.gov/study/NCT01537432
   Google Scholar
• Paul C, Reich K, Gottlieb AB, et al. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1670–1675.
   PubMed Web of Science ®Google Scholar
• Study Record | Beta ClinicalTrials.gov [Internet]. [cited 2023 May 7]. Available from: https://beta.clinicaltrials.gov/study/NCT01169844
   Google Scholar
• Study Record | Beta ClinicalTrials.gov [Internet]. [cited 2023 May 7]. Available from: https://beta.clinicaltrials.gov/study/NCT01109940
   Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis — results of two phase 3 trials. N Engl J Med. 2014 Jul 24;371(4):326–338. doi: 10.1056/NEJMoa1314258
   PubMed Web of Science ®Google Scholar
• McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020 May 9;395(10235):1496–1505. doi: 10.1016/S0140-6736(20)30564-X
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 Sep 19;386(9999):1137–1146. doi: 10.1016/S0140-6736(15)61134-5
   PubMed Web of Science ®Google Scholar
• Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700.1–712.
   Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015 Dec 24;373(26):2534–2548. doi: 10.1056/NEJMoa1505066
   PubMed Web of Science ®Google Scholar
• Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: a randomized phase IIIb study - ACR Meeting Abstracts [Internet]. [cited 2023 Dec 7]. Available from: https://acrabstracts.org/abstract/effect-of-secukinumab-versus-adalimumab-biosimilar-on-radiographic-progression-in-patients-with-radiographic-axial-spondyloarthritis-a-randomized-phase-iiib-study/
   Google Scholar
• Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):19–34.
   PubMed Web of Science ®Google Scholar
• Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a phase 3 double‐blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2021 Apr;35(4):938–947.
   PubMed Web of Science ®Google Scholar
• Brunner HI, Foeldvari I, Alexeeva E, et al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis. 2023 Jan;82(1):154–160.
   PubMed Web of Science ®Google Scholar
• Baer J, Klotsche J, Foeldvari I. Secukinumab in the treatment for patients with juvenile enthesitis related arthritis non-responsive to anti-TNF treatment according the Juvenile Spondyloarthritis Disease Activity Index. Clin Exp Rheumatol. 2022 Mar;40(3):620–624. doi: 10.55563/clinexprheumatol/1u8y08
   PubMed Web of Science ®Google Scholar
• Study Record | Beta ClinicalTrials.gov [Internet]. [cited 2023 May 7]. Available from: https://beta.clinicaltrials.gov/study/NCT04527380
   Google Scholar
• Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111. doi: 10.1186/s13075-019-1882-2
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Deodhar A, Mcinnes IB, et al. Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data. Acta Derm Venereol. 2022 Apr 27;102:563. doi: 10.2340/actadv.v102.563
   PubMed Web of Science ®Google Scholar
• Elewski BE, Baddley JW, Deodhar AA, et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. JAMA Dermatol. 2021 Jan;157(1):43–51.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Deodhar A, Griffiths CEM, et al. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. Br J Dermatol. 2021 Nov;185(5):935–944.
   PubMed Web of Science ®Google Scholar
• Bagri NK, Kumar S, Ramanan AV. Conception of National Biologics Registry for Pediatric Rheumatology: need of the Hour and the way forward. Indian Pediatr. 2022 Dec 15;59(12):913–915. doi: 10.1007/s13312-022-2661-8
   PubMed Web of Science ®Google Scholar
• Search | FDA [Internet]. [cited 2023 May 13]. Available from: https://www.fda.gov/search?s=secukinumab+
   Google Scholar
• EMA. European Medicines Agency. [cited 2023 May 13]. Search the website. Available from: https://www.ema.europa.eu/en/search/search
   Google Scholar
• Ai JW, Zhang S, Ruan QL, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: a metaanalysis of both randomized controlled trials and Registry/Cohort studies. J Rheumatol. 2015 Dec;42(12):2229–2237.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Su G, Kijlstra A, et al. Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis. Prog Retin Eye Res. 2021 Jan 1;80:100866. doi: 10.1016/j.preteyeres.2020.100866
   PubMed Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmol. 2013 Apr 1;120(4):777–787. doi: 10.1016/j.ophtha.2012.09.040
   PubMed Web of Science ®Google Scholar